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Poster Session-II 101that, overall, these 2 regimens allows similar reduced TRM and
high one-year OS for hematological malignancies and could be se-
lected for further phase III comparison with myeloablative regi-
men. Further details of sub-group analysis (disease status; acute
leukemia, NHL and MM) will be presented in order to assess
this conclusion in specific situations with a median study follow-up
of 44 [6 – 78] months.276
APPLICATION OF SECOND GENERATION TYROSINE KINASE INHIBITORS
IN BCR-ABL POSITIVE MALIGNANCIES IN THE POST-TRANSPLANT
PERIOD
Klyuchnikov, E.1,2, Osanmaz, O.1, Schafhausen, P.3, Asenova, S.1,
Zabelina, T.1, Ayuk, F.1, Bruemmendorf, T.3, Zander, A.R.1,
Kroeger, N.1, Bacher, U.1 1 University Cancer Center Hamburg
(UCCH), Hamburg, Germany; 2 St. Petersburg State Pavlovs Medical
University, St.Petersburg, Russian Federation; 3 University Cancer Center
Hamburg (UCCH), Hamburg, Germany
Due to the shift of allogeneic stem cell transplantation (SCT) to
poor risk cases in chronic myeloid leukemia (CML), therapy of
relapse after SCT is highly relevant. In contrast to Imatinib
(IM), where application in stem cell recipients was investigated
in many studies, studies on 2nd generation tyrosine kinase inhib-
itors (TKIs) in the post-transplantat period are limited. We
performed evaluation of 25 stem cell recipients with CML and
13 with Phil positive ALL (Phi1ALL). 9 of those pts received
2nd generation TKIs in the post-transplant period (CML blast
phase; BP: n 5 6; CML accelerated phase; AP: n 5 2; Phi1ALL;
n 5 1). There were 5 males and 4 females (median age 54 years).
Before allo-SCT, 7 were in hematological remission, 8 pts were
MRD positive. 3 pts had Imatinib resistance conferring mutations
(T315I, Y253H, L387F). All pts received unrelated SCT after
myeloablative/reduced conditioning. Indications for the post-
transplant application of dasatinib were as follows: Phi1ALL: mo-
lecular relapse: n 5 1; CML: relapse of BP: n 5 2, extramedullary
CML relapse with skeletal/cutaneous or central nervous manifes-
tations: n 5 4, refractory extramedullary manifestation: n 5 1,
persisting MRD: n 5 1. The median interval between SCT and
dasatinib was 7 months (3–19). Before start of dasatinib after
SCT, 4 cases had been refractory to imatinib. Starting dose of da-
satinib was 2  70 mg or 2  50 mg. Dose escalation was possible
in 3 pts; reduction was necessary in 1 pt. In 1 pt dasatinib was in-
terrupted due to gastrointestinal intolerance/thrombocytopenia.
Median treatment duration was 9 months (range 1–17). 3 cases
showed response to therapy: 1 pt is in stable major mol. remission,
2 other patients are in partial remission of extramedullary relapse.
1 pt suffers from meningeosis leukemica and receives intrathecal
cytarabine. Due to refractoriness, the ALL pt was transferred to
nilotinib. 4 pts (44%) died after 6, 7, 9, and 33 months from
SCT due to progression. Median overall survival after start of da-
satinib was 10 months. In conclusion, although the limited sample
has to be considered, it seems that dasatinib can be administered
with acceptable tolerance in the post-transplant period and is
able to stabilize the situation in single cases of extramedullary or
hematological relapse after SCT even in advanced disease and in
a poor-risk situation. Future prospective studies should further
evaluate the best application schedules of 2nd generation TKIs
in the post-transplant period.277
CLINICAL AND COST OUTCOMES OF DOUBLE UMBILICAL CORD BLOOD
VERSUS BONE MARROW AND PERIPHERAL BLOOD UNRELATED DONOR
HEMATOPOIETIC STEM CELL TRANSPLANTS
Lopez-Gonzalez, G.1, LeMaistre, C.F.1, Bachier, C.1, Smith, B.2,
Chan, K.W.1, Grimley, M.1, Cain, W.1, Delgado, E.1, Kaleel, S.1,
Shaughnessy, P.1 1 Texas Transplant Institute, San Antonio, TX; 2 Alta-
rum, San Antonio, TX
Umbilical cord blood (UCB) is a viable source of hematopoietic
stem cells (HSC) however, because of the risk of nonengraftment
with low total nucleated cell counts (TNC) per kg, double UCB
(DCB) transplants are used in larger patients (pts). We conducteda retrospective review of DCB transplants (n 5 30) from January
2004 through April 2008 compared to bone marrow (n 5 23,
30%) and peripheral blood (n 5 54, 70%) unrelated donor (UD)
transplants during the same time period. Median age was 21 yrs
(range 13–66) for DCB recipients and 45 yrs (range 0.4–67) for
UD pts. UD pts were HLA typed at A, B, C, DR, and DQ and
matched with donors at 9(10) (21%) and 10(10) (79%) loci [all
mismatches at class I alleles]. DCB recipients had HLA matches
of 6/6, 5/6/, 4/6 and 3/6 as follows: (cord 1/ cord 2): (0.0%/
6.7%), (20.0%/30.0%), (76.7%/63.3%), (3.3%/0.0%). The
median TNC/kg in DCB pts was 2.03  107 (range 7.9  106 –
9.3  108). Median day to ANC.500/ul for DCB and UD pts
was 23 days (range 6–66) and 15 days (range 7–52), and platelet
.20,000/ul was 52 days (range 7–130) and 19 days (range 9–63), re-
spectively. Incidences of acute GVHD $2 and chronic GVHD in
the UD and DCB pts were 61.0% and 51% vs. 53.3% and 45%, re-
spectively. Median follow-up was 143 days (range 12–847) for the
DCB group and 242 days (range 34–1506) for the UD pts. Esti-
mated overall survival (OS) at 1 year was 61% (95% CI: 48% to
71%) for UD pts vs. 55% (95% CI: 34% to 72%) in DCB pts
(p 5 NS). Estimated transplant related mortality (TRM) at 100
days for UD pt was 6.5% (95% CI: 2.8% to 14.9%) and 16.7%
(95% CI: 7.3% to 35.5%) (p5 0.09) in DCB pts. All facility trans-
plant related costs were reviewed from the transplant center thru
the first year post transplant, excluding pretransplant workup and
care not received at the transplant center. The total median costs
for DCB transplants were significantly more than the UD costs
at D30, D100 and 1yr post transplant by differences of $42,067,
$50,806, and $52,297, respectively (p\0.05 for each time interval).
The median length of stay for initial hospitalization at start of
preparative regimen was 22 days (2–144) in the UD pts and 29
days (6–103) in the DCB pts, and 60% of total median costs oc-
curred by D30 in the DCB group compared to 52% in the UD
group. In conclusion, DCB provides a viable option for HSC
with comparable clinical outcomes to UD transplants, however
DCB transplants are more expensive primarily because of inpatient
costs in the first 30 days.278
BUILDING AN ETHNICALLY DIVERSE CORD BLOOD INVENTORY: A
SINGLE INSTITUTION’S INITIATIVE TO INCREASE AFRICAN AMERICAN
DONATIONS
Triplett, B.1, Wofford, J.2, Mueckl, K.2, Regan, D.2, Geiler, V.2 1 SSM
Cardinal Glennon Children’s Medical Center/Saint Louis University,
St. Louis, MO; 2 The St. Louis Cord Blood Bank At SSM Cardinal Glen-
non Children’s Medical Center, St. Louis, MO
In 2005, the United States Congress passed the Stem Cell
Therapeutic and Research Act. A central component of this leg-
islation was the development of the National Cord Blood Inven-
tory (NCBI). A competitive bidding process was instituted and to
date three cohorts of banks have been funded with the charge to
collect and store 150,000 new cord blood units. A goal in the de-
velopment of this new inventory is to increase the number of cord
blood units from underrepresented racial and ethnic groups. The
St. Louis Cord Blood Bank (SLCBB) began participating in this
program in September of 2007. The focus for our bank in achiev-
ing the goal of diversification was to establish strategies for re-
cruiting African American donors. Historically, this ethnic
group has not widely participated in cord blood donation in the
St. Louis area. A pilot study was instituted by the SLCBB at
SSM St. Mary’s Health Center in October of 2007. This hospital
was chosen due to its diverse patient population. We hypothe-
sized that the insertion of a dedicated staff nurse into this facility,
to educate and communicate directly with potential donors,
would result in a significant increase in donations from African
Americans. The results from this study are dramatic. A total of
448 cord blood units were collected during the study period (Oc-
tober 1, 2007 – September 30, 2008) as compared to 54 cord
blood units during the previous 12 month period (p 5
\0.0001). This equates to a 730% increase in African American
donations. This pilot study demonstrated that the SLCBB initia-
tive was successful not only in increasing the donation rate among
African Americans, but also an awareness of the life-saving bene-
fits of cord blood. While donations have increased at a significant
102 Poster Session-IIrate, the proportion of these units meeting storage criteria is low.
Of the 448 units collected in this study, only 19.2% met banking
guidelines as compared to 22.0% for Caucasians, 26.7% for
Asians, and 20.0% for Hispanics. African American units not
meeting storage criteria were deferred primarily for low volume
(54.7%) and total nucleated cell count (25.2%). Acknowledging
that biologic factors negatively impact the recovery of nucleated
cells from cord blood collected from this population, the SLCBB
is currently designing a Phase II study to assess alternative
methods to increase collection volumes and cellular yield for
African American donors.279
T-CELL ENGRAFTMENT KINETICS FOLLOWING MYELOABLATIVE AND
NONMYELOABLATIVE REGIMENS FOR ALLOGENEIC HEMATOPOIETIC
TRANSPLANTATION
Mickelson, D.1, Sproat, L.3, Dean, R.2, Sobecks, R.2, Rybicki, L.2,
Kalaycio, M.2, Pohlman, B.2, Sweetenham, J.2, Andresen, S.2,
Bolwell, B.2, Copelan, E.2 1 Cleveland Clinic, Cleveland, OH; 2 Cleveland
Clinic, Taussig Cancer Institute, Cleveland, OH; 3 Cleveland Clinic,
Cleveland, OH
Monitoring of T-cell chimerism after nonmyeloablative(NMA)
regimens has been used to identify patients at risk for graft rejection,
relapse and acute and chronic graft-versus host disease and to deter-
mine use and timing of donor lymphocyte infusions. Followingmye-
loablative (MA) transplantation chimerism studies are not considered
useful because T-cell engraftment is thought to occur rapidly . We
analyzed T-cell engraftment following NMA (fludarabine/TBI)
and after MA transplantation generally busulfan-based. T-cell chi-
merism was studied in 116 patients following MA (busulfan-based
in 72) and 99 patients following NMA transplantation between 5/
2000 and 11/2007, using STR of CD31 cells at 30, 60 and 90 days.
The estimated median interval to T-cells $ 50% donor was 29
days after MA and 27 days after NMA and to T-cells$90% donor
was 42 and 44 days respectively. Comparing only the 72 patients
receiving busulfan based MA preparation to the NMA patients,
T-cell chimerism$10% (p\0.001) and$50% (p5 0.029) occurred
more quickly after NMA transplantation. There was no difference
(p 5 0.68) in the interval to$90% donor T-cells. T-cell
chimerism.50% was associated with more acute GVHD (p 5
0.02), less graft rejection (p\0.001) and less relapse (p5 0.05) follow-
ing NMA regimens, while T-cell chimerism.90% was associated
with more chronic GVHD (p 5 0.002). In MA transplants,
chimerism.50% and .90% were associated with more acute
GVHD (p 5 0.04, p 5 0.009), and chimerism.90% was associated
withmore chronicGVHD (p5 0.07). InNMA,multivariate analysis
found that patients with AML (p5 0.02) and more prior chemother-
apy(p50.04)weremore likely to reach chimerism.50%,while those
with a diagnosis of AML (p5 0.04), MDS (p5 0.002) or CLL (p5
0.05) were more likely to reach chimerism.90%. In MA, multivari-
ate analysis found that patients with more prior chemotherapy (p 5
0.05) and peripheral stem cells (p5 0.008) were more likely to reach
chimerism.90%. These data demonstrated that T-cell engraftment
occurred more quickly in NMA thanMA transplants using busulfan.
Factors predictive of T-cell engraftment kinetics were similar in
NMA and MA transplantation. The preparative regimen is only
one of many factors determining the kinetics of T-cell engraftment.
Designation of a regimen as myeloablative does not correlate with
more rapid or complete T-cell engraftment.
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PRE-EMPTIVE TREATMENTWITH CIDOFOVIR FOR SYMPTOMATIC BK VI-
RUS POSITIVE PATIENTS WHO UNDERWENT ALLOGENEIC STEM CELL
TRANSPLANT REDUCES THE RISK OF PROGRESSION TO HEMORRHAGIC
CYSTITIS
Bilodeau, A., Phillips, J., Mapara, M., Raptis, A., Hou, J.-Z., Agha, M.
Univ. of Pittsburgh Medical Center, Pittsburgh, PA
We have previously demonstrated that Polyomavirus BK asso-
ciated hemorrhagic cystitis is becoming an increasingly recog-
nized complication of HSCT. Our previously published
retrospective analysis demonstrated that BKV was observed in
48% of patients undergoing an allogeneic stem cell transplant
and 16% of them developed hemorrhagic cystitis. Based on therecent findings, we designed a prospective protocol for pre-emp-
tive treatment with Cidofovir for symptomatic BK Viruria. 39
patients underwent an allogeneic stem cell transplant from either
an HLA-matched sibling or unrelated donor during fiscal year
2008. Patients who manifested urological symptoms received Ci-
dofovir 375mg IV QOW until all symptoms resolved. Out of 39
of these patients, 59% (23/39) developed BK virus infection
determined using quantitative real-time PCR assay. Out of these
23 patients, 61% (14/23) received a myeloablative conditioning
regimen (Bu/Cy, TBI/Cy) and 39% (9/23) a non myeloablative
(Flu/TBI, Flu/Cy/Rituxan, Cy/ATG/TBI, TBIx1, Flu/Mel/
Campath, Flu/Cy/TBI). 30% (7/23) became symptomatic and
subsequently received Cidofovir 375mg IV QOW which was
continued until all symptoms resolved and 71% (5/7) also re-
ceived Ciprofloxacin. 57% (4/7) had Graft Versus Host Disease
and 86% (6/7) were concurrently receiving high dose steroid
therapy. 71% (5/7) developed mild hematuria and 29% (2/7) de-
veloped small thrombus in the urine. The mean of total Cidofo-
vir doses received was three and the two patients who developed
mild hematuria with thrombus received 5 and 6 doses respec-
tively. Bone marrow suppression was noted in three patients
who received Cidofovir which was consequently either held or
completely discontinued. All 7 patients had complete resolution
of symptoms, and none developed any clinical manifestations of
hemorrhagic cystitis defined as gross hematuria or the need of
continuous bladder irrigation. There was no correlation with
symptoms and BK virus PCR titers. In conclusion, pre-emptive
treatment of symptomatic BK Viruria with Cidofovir in the allo-
geneic stem cell transplant setting is safe and effective and poten-
tially prevents the progression to BK virus induced hemorrhagic
cystitis.281
GERIATRIC ASSESSMENT (GA) MAY IDENTIFY VULNERABLE OLDER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) RECIPI-
ENTS
Swanson, K.1, van Besien, K.1, Extermann, M.2, Rich, E.1, Stock, W.1,
Larson, R.1, Artz, A.1 1 University of Chicago; 2 University of Florida,
Moffitt Cancer Center
Comorbidity indices and performance status (PS) have been the
primary tools used to predict HCT tolerance; however, these tools
suffer from poor discriminative capacity. Geriatric Assessment
(GA) has found widespread application to assess reduced physio-
logic reserve (i.e. vulnerability) among elderly adults. We hypoth-
esized that a modified GA would identify vulnerable HCT
recipients 50 years and older. We supplemented the standard
pre-HCT evaluation (e.g. history, laboratory, PFT’s) with a pro-
spective GA integrating multiple geriatric domains. Among 94 pa-
tients (pts) 50 years and older, 91 consented to the GA. The
median age was 58 (range 50 – 72). Conditioning regimens were
primarily fludarabine/melphalan, fludarabine/busulfan, and clo-
farabine/melphalan with alemtuzumab and tacrolimus for immu-
nosuppression. The comorbidity domain was scored using four
tools: Charlson Comorbidity Index (CCI), Kaplan Feinstein Scale
(KF), Hematopoietic Cell Transplantation-Comorbidity Index
(HCT-CI) and the Cumulative Illness Rating Scale-Geriatric
(CIRS-G). Functional domains were estimated by PS, frailty index
(FI), and the physical health portion of the short form 36 (SF36-
PH) whereas the mental health portion of the SF36 (SF36-MH)
measured mental health. Activities of daily living (ADL) and in-
strumental ADL (IADL) assessed disability. Table 1 describes
the results and variation detected by each tool within each geriat-
ric domain. For comorbidity, the CIRS-G was the most sensitive
tool as every pt showed comorbidity. Among functional measures,
PS was normal (i.e. PS 5 0) in most pts (64%). Only 4% had a PS
of 2. In contrast, the FI and SF36-PH demonstrated functional
limitations in the majority of pts. Specifically, 52% were
‘‘pre-frail’’ (FI of 1 – 2) and 29% were frail (FI of 3–5). Disability
by ADL or IADL was rare. A modified GA in older HCT recipi-
ents is feasible and may reveal abnormalities in multiple geriatric
domains suggesting vulnerability not recognized by a standard
evaluation. Ongoing studies will determine the predictive validity
of specific domains within the GA.
